, 24 ). Our dataset does not have the power to examine risk factors for peroperative hemodynamic instability but while keeping this limitation in mind, it suggests that medical pretreatment with PBZ titrated to orthostatic hypotension reduces
Search Results
Randi Ugleholdt, Åse Krogh Rasmussen, Pernille A H Haderslev, Bjarne Kromann-Andersen, and Claus Larsen Feltoft
Debra M Gordon, Pablo Beckers, Emilie Castermans, Sebastian J C M M Neggers, Liliya Rostomyan, Vincent Bours, Patrick Petrossians, Vinciane Dideberg, Albert Beckers, and Adrian F Daly
SDHB . High-power (A) and low-power (B) H&E staining images of metastatic pheochromocytoma deposits in the iliac and peri-vesicular lymph nodes at presentation. CT (C) and PET-CT (D) images showing metastatic deposits of pheochromocytoma in the pelvic
R Perchard, L Magee, A Whatmore, F Ivison, P Murray, A Stevens, M Z Mughal, S Ehtisham, J Campbell, S Ainsworth, M Marshall, M Bone, I Doughty, and P E Clayton
pilot study is the small sample size, which has insufficient power to detect a small effect size. Our findings must therefore be interpreted with caution, and a larger, adequately powered study is required. Another limitation is that there are many
Hathairat Rueangdetnarong, Rattanaporn Sekararithi, Thidarat Jaiwongkam, Sirinart Kumfu, Nipon Chattipakorn, Theera Tongsong, and Phudit Jatavan
of the two groups are equivalent, this study needed a sample size at least 19 cases in each group to gain power of 90% at 95% confidence interval and testing margin of 1%. Statistical analysis Statistical analyses were performed by SPSS
Simonetta Piana, Eleonora Zanetti, Alessandra Bisagni, Alessia Ciarrocchi, Davide Giordano, Federica Torricelli, Teresa Rossi, and Moira Ragazzi
microcarcinoma and in the normal surrounding thyroid tissue. (A and B) H&E staining (in B microcarcinoma at higher power view). (C and D) NOTCH1 staining. NOTCH1 positivity is restricted to microcarcinoma (in the center; in D at higher power view), while normal
Hershel Raff and Hariprasad Trivedi
considering the extremely low probability that any of the ESRD patients had endogenous Cushing's syndrome. This is similar to previous studies in patients with diabetes mellitus (37) . It is important to reiterate that this study was powered to compare the
Anna Malczewska, Kjell Oberg, and Beata Kos-Kudla
score cut-off: 20. Statistical analysis The sample size needed to detect significant differences in CgA levels per assay (from previously published mean ± s.e.m. , using a power of 0.8 and α = 0.05) was calculated to be a minimum of 210
Danielle Christine Maria van der Kaay, Anne Rochtus, Gerhard Binder, Ingo Kurth, Dirk Prawitt, Irène Netchine, Gudmundur Johannsson, Anita C S Hokken-Koelega, Miriam Elbracht, and Thomas Eggermann
and the public health issues (‘when to test what’). In this review, we illustrate the power of current and future comprehensive molecular genetic strategies for an accurate and personalized diagnosis and assess their appropriate use. Clinical
Elizabeth J de Koster, Olga Husson, Eveline W C M van Dam, G Sophie Mijnhout, Romana T Netea-Maier, Wim J G Oyen, Marieke Snel, Lioe-Fee de Geus-Oei, Dennis Vriens, and
acquired during a randomised controlled trial, the study was not a priori powered to distinguish HRQoL effects ( 6 ). Post hoc sensitivity analysis, however, showed that in the smallest cohort (i.e. active surveillance group, n = 23) we have 80% power
Dmitry M Davydov and Malik K Nurbekov
power = 0.80 with β = 0.60, dominant allele frequency = 0.54 and mean ( s.d .) of FPG = 5.3 (0.7) mmol/L obtained from a previous study and accepted for a group of subjects without diabetes ( 39 ). Additional 43 subjects were included in the patient
